Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call November 7, 2024 8:00 AM ET

Company Participants

Alina Venezia - Director, Investor Relations
Sheldon Koenig - President and Chief Executive Officer
Ben Halladay - Chief Financial Officer
Betty Jean Swartz - Chief Business Officer
Eric Warren - Chief Commercial Officer

Conference Call Participants

Dennis Ding - Jefferies
Serge Belanger - Needham
Jason Zemansky - Bank of America
Lander Egaña-Gorroño - H.C. Wainwright
Tom Shrader - BTIG

Operator

Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today’s conference call may be recorded. I would now like to hand the conference over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. Please go ahead.

Alina Venezia

Thank you, operator. Good morning, and welcome to Esperion’s third quarter 2024 earnings conference call. With us today are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the executive team will be available for Q&A following our prepared remarks.

We issued a press release earlier this morning detailing the content of today’s call. A copy can be found on the Investor page of our website together with a copy of the presentation that we will also be referencing. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to the risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today’s press release and in our SEC filings.

The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 7, 2024. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast. As a reminder, this conference call and webcast are being recorded and archived. We will begin the call with prepared remarks and then open the line for your questions.

I now turn the call over to Sheldon.

Sheldon Koenig

Thank you, Alina. Good morning, everyone, and thank you for joining us. As I look back over the past year, I continue to be so proud of all our team has accomplished. It has truly been a watershed year for Esperion, in which we successfully expanded our NEXLETOL, NEXLIZET labels to include broad new indications for primary and secondary cardiovascular risk reduction, scaled up our commercial team and launched these new indications and broaden payer access and implemented marketing programs that have enhanced awareness of our new indications among health care providers to drive prescription growth.